Chugai stock drops the most since 1977 on disappointing obesity drug data
A study showed the drug, which it has licensed to Eli Lilly & Co., resulted in lower weight loss and higher rates of nausea and vomiting than anticipated.

Join our subscribers list to get the latest news, updates and special offers directly in your inbox
Tomas Kauer - News Moderator May 1, 2025